Literature DB >> 35881183

Quantitative susceptibility mapping demonstrates different patterns of iron overload in subtypes of early-onset Alzheimer's disease.

Grégory Kuchcinski1,2,3, Lucas Patin4, Renaud Lopes5,6, Mélanie Leroy7, Xavier Delbeuck7, Adeline Rollin-Sillaire7,8, Thibaud Lebouvier5,7,8, Yi Wang9, Pascal Spincemaille9, Thomas Tourdias10,11, Lotfi Hacein-Bey12, David Devos5,13, Florence Pasquier5,7,8, Xavier Leclerc5,6,4, Jean-Pierre Pruvo5,6,4, Sébastien Verclytte14.   

Abstract

OBJECTIVES: We aimed to define brain iron distribution patterns in subtypes of early-onset Alzheimer's disease (EOAD) by the use of quantitative susceptibility mapping (QSM).
METHODS: EOAD patients prospectively underwent MRI on a 3-T scanner and concomitant clinical and neuropsychological evaluation, between 2016 and 2019. An age-matched control group was constituted of cognitively healthy participants at risk of developing AD. Volumetry of the hippocampus and cerebral cortex was performed on 3DT1 images. EOAD subtypes were defined according to the hippocampal to cortical volume ratio (HV:CTV). Limbic-predominant atrophy (LPMRI) is referred to HV:CTV ratios below the 25th percentile, hippocampal-sparing (HpSpMRI) above the 75th percentile, and typical-AD between the 25th and 75th percentile. Brain iron was estimated using QSM. QSM analyses were made voxel-wise and in 7 regions of interest within deep gray nuclei and limbic structures. Iron distribution in EOAD subtypes and controls was compared using an ANOVA.
RESULTS: Sixty-eight EOAD patients and 43 controls were evaluated. QSM values were significantly higher in deep gray nuclei (p < 0.001) and limbic structures (p = 0.04) of EOAD patients compared to controls. Among EOAD subtypes, HpSpMRI had the highest QSM values in deep gray nuclei (p < 0.001) whereas the highest QSM values in limbic structures were observed in LPMRI (p = 0.005). QSM in deep gray nuclei had an AUC = 0.92 in discriminating HpSpMRI and controls.
CONCLUSIONS: In early-onset Alzheimer's disease patients, we observed significant variations of iron distribution reflecting the pattern of brain atrophy. Iron overload in deep gray nuclei could help to identify patients with atypical presentation of Alzheimer's disease. KEY POINTS: • In early-onset AD patients, QSM indicated a significant brain iron overload in comparison with age-matched controls. • Iron load in limbic structures was higher in participants with limbic-predominant subtype. • Iron load in deep nuclei was more important in participants with hippocampal-sparing subtype.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Alzheimer disease; Atrophy; Iron; Magnetic resonance imaging; Quantitative susceptibility mapping

Year:  2022        PMID: 35881183     DOI: 10.1007/s00330-022-09014-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  19 in total

1.  Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging.

Authors:  T E J Behrens; H Johansen-Berg; M W Woolrich; S M Smith; C A M Wheeler-Kingshott; P A Boulby; G J Barker; E L Sillery; K Sheehan; O Ciccarelli; A J Thompson; J M Brady; P M Matthews
Journal:  Nat Neurosci       Date:  2003-07       Impact factor: 24.884

2.  Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography.

Authors:  Andri C Tziortzi; Suzanne N Haber; Graham E Searle; Charalampos Tsoumpas; Christopher J Long; Paul Shotbolt; Gwenaelle Douaud; Saad Jbabdi; Timothy E J Behrens; Eugenii A Rabiner; Mark Jenkinson; Roger N Gunn
Journal:  Cereb Cortex       Date:  2013-01-02       Impact factor: 5.357

3.  7T T₂*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease.

Authors:  Sanneke van Rooden; Nhat Trung Doan; Maarten J Versluis; Jeroen D C Goos; Andrew G Webb; Ania M Oleksik; Wiesje M van der Flier; Philip Scheltens; Frederik Barkhof; Annelies W E Weverling-Rynsburger; Gerard Jan Blauw; Johan H C Reiber; Mark A van Buchem; Julien Milles; Jeroen van der Grond
Journal:  Neurobiol Aging       Date:  2014-07-15       Impact factor: 4.673

4.  Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease.

Authors:  Michael M Zeineh; Yuanxin Chen; Hagen H Kitzler; Robert Hammond; Hannes Vogel; Brian K Rutt
Journal:  Neurobiol Aging       Date:  2015-06-06       Impact factor: 4.673

5.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

6.  In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI.

Authors:  G Bartzokis; D Sultzer; J Mintz; L E Holt; P Marx; C K Phelan; S R Marder
Journal:  Biol Psychiatry       Date:  1994-04-01       Impact factor: 13.382

7.  Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, Part XII.

Authors:  E Koss; S Edland; G Fillenbaum; R Mohs; C Clark; D Galasko; J C Morris
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

8.  Early-onset Alzheimer's disease is associated with greater pathologic burden.

Authors:  Gad A Marshall; Lynn A Fairbanks; Sibel Tekin; Harry V Vinters; Jeffrey L Cummings
Journal:  J Geriatr Psychiatry Neurol       Date:  2007-03       Impact factor: 2.680

9.  In vivo quantitative susceptibility mapping (QSM) in Alzheimer's disease.

Authors:  Julio Acosta-Cabronero; Guy B Williams; Arturo Cardenas-Blanco; Robert J Arnold; Victoria Lupson; Peter J Nestor
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

10.  Biological subtypes of Alzheimer disease: A systematic review and meta-analysis.

Authors:  Daniel Ferreira; Agneta Nordberg; Eric Westman
Journal:  Neurology       Date:  2020-02-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.